

7th December 2010

Companies Announcement Office
ASX Limited
Exchange Centre
20 Bridge Street
Sydney NSW 2000

PRICE QUERY RESPONSE

I refer to the ASX price query yesterday regarding the change in price of the Company's shares from a close of \$0.054 on 29th November 2010 to a high of \$0.074 at the time of your letter to the Company.

In response to your queries, and adopting your numbering, the Company advises as set out below:

1. No. The Company is unaware of any information concerning it that has not been announced that, if known, could be an explanation for recent trading in the securities.

Subsequent to the Company's AGM the CEO Dr Geoff Cumming gave an interview on Boardroom Radio that was released to the market on 1st December 2010.

Please refer to **Appendix A** for a full transcript of this interview.

In that interview Dr Cumming did NOT say that the Company is "perilously close" to having <u>many</u> signatures for its new Mix&Go technology. What Dr Cumming said is that a large number of companies are assessing the technology in their own hands and that "some are now perilously close to making a decision".

What this was intended to convey was that some of the assessments that are being undertaken by potential users of Mix&Go are, in Anteo's belief, drawing to a close and some decisions, positive or negative, are therefore likely to be communicated to Anteo.

Dr Cumming went on to say that "we have no reason to be concerned that the decision will be anything other than positive." The basis for this comment, is the feedback received from those companies testing Mix&Go has suggested that the technology has performed in their hands as it does in Anteo's, provided Anteo's protocols for use of the technology are followed. Assuming these positive results continue to be obtained, Anteo would expect that the companies undertaking the testing will choose to enter into a commercial transaction with Anteo given the cost and performance benefits that accrue from the use of Mix&Go. The companies assessing Mix&Go need to come to this conclusion themselves.



- 2. Not Applicable
- 3. The Company is not aware of any other explanation for the price change and increase in volumes in the securities of the Company.
- 4. The Company confirms it is in compliance with Listing Rules, including Rule 3.1

Yours Faithfully,

lames Henderson

Non Executive Chairman

For further information please contact:

Dr Geoff Cumming, CEO, Anteo Diagnostics Limited

Tel: +612 8823 3110

Mr James Henderson, Non Executive Chairman, Anteo Diagnostics Limited

Tel: +612 8823 3100



Appendix A

Transcript of Board Room Radio Interview conducted with Dr Geoff Cumming and Boardroom Radio ("BRR") and released to ASX on 1st December 2010.

To listen, copy the following details into your web browser: brr.com.au/event/72259

The presentation details are as follows:

- > Anteo AGM Commentary Dr. Geoff Cumming, Chief Executive Officer
- > Presented by Dr. Geoff Cumming, Chief Executive Officer
- > Wed, 1 Dec 2010

Transcript

BRR: Today on BRR I'm pleased to be joined by Dr Geoff Cumming who is the CEO at Anteo Diagnostics. Geoff, thank you very much for joining us today.

CEO: Tom, thanks for having us here. It's a pleasure.

BRR: Geoff, you've just hosted your AGM and another 12 months have obviously passed. Were you pleased with the progress during 2009/2010.

CEO: The short answer, Tom, is "Yes". It's been a tumultuous year for us. This time last year we were really staring death in the face and now, I'd have to say that there is a pretty vibrant feeling within the organisation and a pretty high level of confidence for the future.

BRR: OK. And how have you achieved the turnaround?

CEO: Well, in the end it's the technology that speaks. We've done a number of things. We've obviously promoted it broadly in the relevant markets around the world. We've entered into Confidentiality Agreements with the relevant players. We've given them the opportunity to test it inhouse, and, what is somewhat surprising is that virtually all of the people who have assessed it in house have maintained their level of interest in the product and are continuing to assess it. So, they are very quickly able to determine that what we've told them Mix&Go does can actually be achieved in their own laboratories. Given that the main focus for us has been the pathology market, the IVD market, there's an innate level of conservatism that exists in that market. They want to convince themselves first of all that it works and then make sure that in making a change adverse changes don't flow. So they're in the process of making sure that everything remains as it should and once they have convinced themselves of that we would expect that contracts will be signed.

BRR: OK. So that's going to be the outlook for you, is getting these agreements in place during the next 12 months.



CEO: Absolutely. In fact, in preparation for the AGM I looked at where we were this time last year and compared it with where we are now and the result was that this time last year we were engaged with 14 different groups. Demonstrating the capabilities of Mix&Go to those industry players. We're now dealing with 47 and what is unusual, I think, is that nobody has said "No thanks. It's not for us." It's frustratingly slow but each of those players is now using the process in their own hands and ensuring that there are no adverse actions that flow from positive aspects of the Mix&Go technology. Some of those 47 players are now, I think, perilously close to making a decision and we've got no reason to be concerned that the decision is going to be anything other than positive.

BRR: OK. Well that all sounds positive and we'll look forward to hopefully seeing some signatures come through this year. Thanks very much for joining us today Geoff.

CEO: Thanks very much Tom and nobody is looking forward to those additional signatures more than I.

BRR: Excellent and no doubt we'll have an opportunity to catch up when they come through. Thanks again.

CEO: I Look forward to it. Thanks Tom.



ABN 26 087 780 489 20 Bridge Street Sydney NSW 2000 PO Box H224 Australia Square NSW 1215

> Telephone 61 2 9227 0656 Facsimile 61 2 9241 7620 www.asx.com.au

ASX Compliance Pty Limited

6 December 2010

Mr. Shane Hartwig Company Secretary Anteo Diagnostics Limited Unit 4, 26 Brandl Street Eight Mile Plains QLD 4113

By Email

Dear Shane,

Anteo Diagnostics Limited (the "Company")

RE: PRICE QUERY

We have noted a change in the price of the Company's securities from a close of \$0.054 on 29 November 2010 to a high of \$0.074 today at the time of writing. We have also noted an increase in the volume of trading in the securities over this period.

In light of the price change, please respond to each of the following questions.

1. Is the Company aware of any information concerning it that has not been announced which, if known, could be an explanation for recent trading in the securities of the Company?

In answering this question, please address comments by the CEO of the Company, Dr. Geoffrey Cumming, in a Boardroom Radio Interview on 1 December 2010 (the "Interview") that the Company is "perilously close" to having many signatures for its new Mix & Go technology.

Please note that as recent trading in the Company's securities could indicate that information has ceased to be confidential, the Company is unable to rely on the exceptions to listing rule 3.1 contained in listing rule 3.1A when answering this question.

Please also provide a full transcript of the Interview.

2. If the answer to question 1 is yes, can an announcement be made immediately? If not, why not and when is it expected that an announcement will be made?

Please note, if the answer to question 1 is yes and an announcement cannot be made immediately, you need to contact us to discuss this and you need to consider a trading halt (see below).

- 3. Is there any other explanation that the Company may have for the price change and increase in volume in the securities of the Company?
- 4. Please confirm that the Company is in compliance with the listing rules and, in particular, listing rule 3.1.





Your response should be sent to me by e-mail at Zheng.Li@asx.com.au or by facsimile on facsimile number (02) 9241 7620. It should <u>not</u> be sent to the Company Announcements Office.

Unless the information is required immediately under listing rule 3.1, a response is requested as soon as possible and, in any event, not later than half an hour before the start of trading (ie before 9.30 a.m. A.E.D.T) on Tuesday, 7 December 2010.

Under listing rule 18.7A, a copy of this guery and your response will be released to the market, so your response should be in a suitable form and separately address each of the questions asked. If you have any queries or concerns, please contact me immediately.

Listing rule 3.1

Listing rule 3.1 requires an entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. The exceptions to this requirement are set out in listing rule 3.1A.

In responding to this letter you should consult listing rule 3.1 and Guidance Note 8 - Continuous Disclosure: listing rule 3.1.

If the information requested by this letter is information required to be given to ASX under listing rule 3.1 your obligation is to disclose the information immediately.

Your responsibility under listing rule 3.1 is not confined to, or necessarily satisfied by, answering the questions set out in this letter.

Trading halt

If you are unable to respond by the time requested, or if the answer to question 1 is yes and an announcement cannot be made immediately, you should consider a request for a trading halt in the Company's securities. As set out in listing rule 17.1 and Guidance Note 16 - Trading Halts, we may grant a trading halt at your request. We may require the request to be in writing. We are not required to act on your request. You must tell us each of the following.

- The reasons for the trading halt.
- How long you want the trading halt to last.
- The event you expect to happen that will end the trading halt.
- That you are not aware of any reason why the trading halt should not be granted.
- Any other information necessary to inform the market about the trading halt, or that we ask for.

The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. If a trading halt is requested and granted and you are still unable to reply to this letter before the commencement of trading, suspension from quotation would normally be imposed by us from the commencement of trading if not previously requested by you. The same applies if you have requested a trading halt because you are unable to release information to the market, and are still unable to do so before the commencement of trading.

If you have any gueries regarding any of the above, please let me know.

Yours sincerely,











[Sent electronically without signature]

Kobe Li Adviser, Listings (Sydney)